Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research
The septin-6 family of proteins consist of septin-6, 8, 10, 11 and 14 which may have overlapping functions in cells. Murine single cell mRNA expression data demonstrate that hematopoietic stem and progenitor cells (HSPC) express significant levels of Septin-6, Septin-11 and 8, with little to no expression of Septin-10 and 14. To better understand the functional role of Septin-6, we created lentivirus vectors tagged with a GFP reporter that contained shRNAs against Septin-6. Culture of Septin-6 knockdown (Septin-6 KD) murine HSPC in IMDM (10ng/ml IL-3, 25ng/ml of SCF, TPO, Flt-3 and IL-6) resulted in an average of 18-fold decrease in cell counts compared to controls (p=0.02). This was accompanied by an increase in cell cycle: S-phase: Septin-6 KD 55.7%; controls 42.5%, p=0.05 and a cumulative decrease in the G0/G1 and G2/M phase suggesting that Septin-6 is important in regulating cell cycle in HSPC. Controls were a non-targeting shRNA and an empty vector for all experiments described. Furthermore, knockdown of Septin-6 caused a decrease in total clonogenic activity with defects seen in both myeloid (GM) and erythroid (BFU-E) colonies (Table 1). Competitive repopulation assays, wherein transduced BoyJ HSPC (GFP+ Septin KD and BFP+ control were mixed 1:1) were injected into lethally irradiated C57Bl/6 mice, demonstrated a reduction in multilineage chimerism in the peripheral blood, bone marrow, spleen and thymus in primary and secondary transplant recipients after knockdown of Septin-6 (Table 2). To better define function in specific hematopoietic populations of HSPC, we performed knockdown in FACS-sorted purified cells. Engraftment studies demonstrated a significant reduction in bone marrow chimerism in primary transplant recipients after knockdown of Septin-6 most clearly in ST-HSC (Table 2) with a trend towards a decrease in LT-HSC and MPP. These data support a key role of Septin-6 in murine and human hematopoiesis via alterations in cell cycle and validate the pathogenic nature of a specific mutation in human SEPTIN-6.
Disclosures: Camargo: Fog Pharmaceuticals: Divested equity in a private or publicly-traded company in the past 24 months, Membership on an entity's Board of Directors or advisory committees. Williams: Bluebird: Consultancy, Other: Provides Vector; Chief Scientific Chair, Emerging Therapy Solutions: Consultancy; Scientific Advisory Board, Skyline Therapeutics: Consultancy; Insertion Site Analysis Advisory Board, Bluebird Bio: Consultancy; Scientific Advisory Board, Beam Therapeutics: Consultancy; Orchard Therapeutics: Other: Provides vector; Novartis: Consultancy, Other: Steering Committee (fees donated to NAPAAC); Insertion Site Advisory Board, Biomarin: Consultancy; Novartis: Other: Provision of study materials, medical writing.